IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company's clinical development programs.
"We are pleased to welcome Dr. Katz to the Eledon team," said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. "Dr. Katz brings a wealth of knowledge in the surgical transplantation field together with extensive experience designing and overseeing clinical trials for immunosuppressive treatments. We look forward to his leadership and contributions as we continue to advance tegoprubart for the prevention of rejection in patients undergoing transplantation procedures."
Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis' xenotransplantation programs. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics ...